Apr 12 2024 This Week in Cardiology

ACC Recap #1: DanGer Shock (plus a sobering JAMA research letter on Impella use), REDUCE-AMI, PREVENT, and EMPACT-MI are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
www.medscape.c...
I. DanGer-Shock Trial
Impella CP Improves Survival in STEMI, Cardiogenic Shock www.medscape.c...
Impella Saves Lives in Cardiogenic Shock, but Patient Selection Key www.medscape.c...

• Published DanGer Shock Study www.nejm.org/d...
• JAMA Research letter jamanetwork.co...
II. REDUCE-AMI Trial
New Data Question Beta-Blockers Post-MI With Preserved EF www.medscape.c...
Beta-Blockers Post-MI Past Their Expiration Date: REDUCE-AMI www.medscape.c...

• REDUCE-AMI paper www.nejm.org/d...
• Meta-analysis: Beta Blockers for MI doi.org/10.101...
III. PREVENT Trial
Preventive PCI for Vulnerable Plaques Reduces Cardiac Events
www.medscape.c...
Preventive Coronary Stents: Not There Yet
www.medscape.c...

• PREVENT doi.org/10.101...
IV. EMPACT MI trial of Empagliflozin in the Post-MI setting
Empagliflozin Fails to Reduce Events After Acute MI
www.medscape.c...

• EMPACT-MI: Another SGLT2 Inhibitor Miss in Post-MI Care www.medscape.c...
• EMPACT MI www.nejm.org/d...
• DAPA MI evidence.nejm....
• PARADISE MI www.nejm.org/d...
• Kaul thread x.com/kaulcsmc...
• Kaul paper www.ahajournal...
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. www.medscape.c...
Questions or feedback, please contact [e-mail]